Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial.
- Authors
- Stapleton, John A; Sutherland, Gay
- Year
- 2011
- Journal
- Addiction (Abingdon, England)
- PMID
- 21205043
- DOI
- 10.1111/j.1360-0443.2010.03274.x
AIMS: Of six established nicotine replacement therapy (NRT) formulations, only the gum and patch have been tested without specialist clinic support in placebo-controlled trials. We aimed to broaden the evidence base by examining if the nicotine nasal spray (NNS) could be effective with only brief support in general practice. DESIGN: Randomized placebo-controlled trial. SETTING: Twenty-seven English general practices. PARTICIPANTS: A total of 761 heavy smokers received brief support and 12 weeks of treatment with NNS (506) or placebo (255). MEASUREMENTS: The primary outcome was biochemically verified complete abstinence from smoking throughout weeks 3-12. FINDINGS: NNS compared with placebo more than doubled the number who successfully stopped smoking [15.4% versus 6.7%, odds ratio (OR) = 2.6, 95% confidence interval (CI) = 1.5-4.4]. Many participants reported minor irritant adverse symptoms. NNS was particularly effective among those who were more highly dependent on nicotine (OR = 6.17, 95% CI = 2.13-17.9). Of those who failed to stop during the first week (417, 54.8%), only one (0.2%) achieved later success. CONCLUSIONS: NNS is effective when given in primary care. The benefit was lower than in a specialist clinic but similar to that with the nicotine patch in primary care. Unlike most other NRT formulations, bupropion or varenicline, NNS was especially helpful for more dependent smokers. Continuing treatment of those initially failing was not beneficial. An initial 1-week prescription to those more dependent on nicotine is likely to be the most cost-effective NNS treatment protocol. These results should offer support to the effectiveness of the other NRT formulations untested in this setting.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | 2012 | 22648373 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nicotine replacement therapy and oral health: a network meta-analysis of adverse effects in randomized trials. | Sivaramakrishnan G et al. | — | 2025 | → |
| Study title: A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use. | Kim MM et al. | — | 2023 | → |
| Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. | Thomas KH et al. | — | 2022 | → |
| Interventions for preventing weight gain after smoking cessation. | Hartmann-Boyce J et al. | — | 2021 | → |
| Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. | Thomas KH et al. | — | 2021 | → |
| Item Response Theory analysis of Fagerström Test for Cigarette Dependence. | Svicher A et al. | — | 2018 | → |
| Nicotine replacement therapy versus control for smoking cessation. | Hartmann-Boyce J et al. | — | 2018 | → |
| [Psychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency]. | Batra A et al. | — | 2016 | → |
| Cigarette smoke-induced mitochondrial fragmentation and dysfunction in human airway smooth muscle. | Aravamudan B et al. | — | 2014 | → |
| Short-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. | Scherphof CS et al. | — | 2014 | → |
| Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy. | Tonstad S et al. | — | 2014 | → |
| Recruiting and engaging smokers in treatment in a primary care setting: developing a chronic care model implemented through a modified electronic health record. | Piper ME et al. | — | 2013 | → |
| Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. | Bedi G et al. | — | 2013 | → |
| The effect of reducing the threshold for carbon monoxide validation of smoking abstinence--evidence from the English Stop Smoking Services. | Brose LS et al. | — | 2013 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Interventions for preventing weight gain after smoking cessation. | Farley AC et al. | — | 2012 | → |
| Nicotine replacement therapy for smoking cessation. | Stead LF et al. | — | 2012 | → |
| The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. | Fagerström K et al. | — | 2012 | → |
| Implementing public health in secondary care: a Rotherham perspective on strategy development and implementation. | Al-Alawy K et al. | — | 2011 | → |